HCQ could also prevent β2-glycoprotein I complex from binding to phospholipid bilayers and cells and protect the annexin A5 anticoagulant shield from being destroyed by antiphospholipid antibodies, which was considered to decrease the risk of thrombosis in APS and SLE (69, 70). This evidence concerns the gene ANXA5 and Venous thrombosis.